Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE

NCT04819113 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04819113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04819113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
April 9, 2021
Completion date
September 9, 2022
Enrollment
149 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal vaccine